The secondary endpoints evaluate the eicacy of patisiran vs placebo over 12 months in a hierarchical manner with the following measures Healthrelated quality of life with the KCCQ change from baseline at 12 months Composite of allcause mortality frequency of cardiovascular CV events CV hospitalizations and urgent heart failure HF visits and change from baseline in 6MWT Composite of allcause mortality and frequency of allcause hospitalizations and urgent HF visits in patients not on tafamidis at baseline and Composite of allcause mortality and frequency of allcause hospitalizations and urgent HF visits in the overall study population